2017 Seattle Patient & Survivor Conference
What is Immunotherapy?
Managing Drug Side Effects

From the Pressroom

FDA Approves Adjuvant Sunitinib for High-Risk RCC

The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who h…

Continue Reading

Dr. Escudier: The Future of RCC Treatment

Bernard Escudier, MD, is the former chair of the genitourinary group of the Institut Gustave Roussy in Villejuif, Fran…

Continue Reading

Phase III IMmotion151 Study Met Co-primary Goal In Kidney Cancer

The study demonstrated that the combination of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) provided a statistical…

Continue Reading